Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Cytokine Measurements for Diagnosing and Characterizing Leukemoid Reactions and Immunohistochemical Validation of a Granulocyte Colony-Stimulating Factor and CXCL8-Producing Renal Cell Carcinoma.

Åström M, Tajeddinn W, Karlsson MG, Linder O, Palmblad J, Lindblad P.

Biomark Insights. 2018 Aug 17;13:1177271918792246. doi: 10.1177/1177271918792246. eCollection 2018.

2.

Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry.

Blimark CH, Turesson I, Genell A, Ahlberg L, Björkstrand B, Carlson K, Forsberg K, Juliusson G, Linder O, Mellqvist UH, Nahi H, Kristinsson SY; Swedish Myeloma Registry.

Haematologica. 2018 Mar;103(3):506-513. doi: 10.3324/haematol.2017.178103. Epub 2017 Dec 7.

3.

Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register.

Nahi H, Genell A, Wålinder G, Uttervall K, Juliusson G, Karin F, Hansson M, Svensson R, Linder O, Carlson K, Björkstrand B, Kristinsson SY, Mellqvist UH, Blimark C, Turesson I.

Eur J Haematol. 2017 Sep;99(3):216-222. doi: 10.1111/ejh.12907. Epub 2017 Jun 28.

PMID:
28544116
4.

Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation in Sweden, long-term results from all patients treated in 1994-2009.

Rosengren S, Mellqvist UH, Nahi H, Forsberg K, Lenhoff S, Strömberg O, Ahlberg L, Linder O, Carlson K.

Bone Marrow Transplant. 2016 Dec;51(12):1569-1572. doi: 10.1038/bmt.2016.249. Epub 2016 Oct 3.

PMID:
27694943
5.

Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial.

Gimsing P, Hjertner Ø, Abildgaard N, Andersen NF, Dahl TG, Gregersen H, Klausen TW, Mellqvist UH, Linder O, Lindås R, Tøffner Clausen N, Lenhoff S.

Bone Marrow Transplant. 2015 Oct;50(10):1306-11. doi: 10.1038/bmt.2015.125. Epub 2015 Jun 29.

6.

Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat.

Andersen CL, Bjørn ME, McMullin MF, Harrison C, Samuelsson J, Ejerblad E, Zweegman S, Fernandes S, Bareford D, Knapper S, Löfvenberg E, Linder O, Andreasson B, Ahlstrand E, Jensen MK, Bjerrum OW, Vestergaard H, Larsen H, Klausen TW, Mourits-Andersen T, Skov V, Thomassen M, Kruse T, Grønbæk K, Hasselbalch HC.

Leuk Res. 2014 Jul;38(7):816-21. doi: 10.1016/j.leukres.2014.04.002. Epub 2014 Apr 14.

PMID:
24836761
7.

A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia.

Andersen CL, McMullin MF, Ejerblad E, Zweegman S, Harrison C, Fernandes S, Bareford D, Knapper S, Samuelsson J, Löfvenberg E, Linder O, Andreasson B, Ahlstrand E, Jensen MK, Bjerrum OW, Vestergaard H, Larsen H, Klausen TW, Mourits-Andersen T, Hasselbalch HC.

Br J Haematol. 2013 Aug;162(4):498-508. doi: 10.1111/bjh.12416. Epub 2013 Jun 11.

PMID:
23758082
8.

Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study.

Hjorth M, Hjertner Ø, Knudsen LM, Gulbrandsen N, Holmberg E, Pedersen PT, Andersen NF, Andréasson B, Billström R, Carlson K, Carlsson MS, Flogegård M, Forsberg K, Gimsing P, Karlsson T, Linder O, Nahi H, Othzén A, Swedin A; Nordic Myeloma Study Group (NMSG).

Eur J Haematol. 2012 Jun;88(6):485-96. doi: 10.1111/j.1600-0609.2012.01775.x. Epub 2012 Mar 30.

9.

Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.

Möllgård L, Saft L, Treppendahl MB, Dybedal I, Nørgaard JM, Astermark J, Ejerblad E, Garelius H, Dufva IH, Jansson M, Jädersten M, Kjeldsen L, Linder O, Nilsson L, Vestergaard H, Porwit A, Grønbæk K, Hellström-Lindberg E.

Haematologica. 2011 Jul;96(7):963-71. doi: 10.3324/haematol.2010.039669. Erratum in: Haematologica. 2011 Aug;96(8):1240. Lindberg, Eva Hellström [corrected to Hellström-Lindberg, Eva].

10.

Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms.

Björkholm M, Derolf AR, Hultcrantz M, Kristinsson SY, Ekstrand C, Goldin LR, Andreasson B, Birgegård G, Linder O, Malm C, Markevärn B, Nilsson L, Samuelsson J, Granath F, Landgren O.

J Clin Oncol. 2011 Jun 10;29(17):2410-5. doi: 10.1200/JCO.2011.34.7542. Epub 2011 May 2.

11.

Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial.

Gimsing P, Carlson K, Turesson I, Fayers P, Waage A, Vangsted A, Mylin A, Gluud C, Juliusson G, Gregersen H, Hjorth-Hansen H, Nesthus I, Dahl IM, Westin J, Nielsen JL, Knudsen LM, Ahlberg L, Hjorth M, Abildgaard N, Andersen NF, Linder O, Wisløff F.

Lancet Oncol. 2010 Oct;11(10):973-82. doi: 10.1016/S1470-2045(10)70198-4.

PMID:
20863761
12.

Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy.

Grövdal M, Karimi M, Khan R, Aggerholm A, Antunovic P, Astermark J, Bernell P, Engström LM, Kjeldsen L, Linder O, Nilsson L, Olsson A, Holm MS, Tangen JM, Wallvik J, Oberg G, Hokland P, Jacobsen SE, Porwit A, Hellström-Lindberg E.

Br J Haematol. 2010 Aug;150(3):293-302. doi: 10.1111/j.1365-2141.2010.08235.x. Epub 2010 May 20.

PMID:
20497178
13.

Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.

Waage A, Gimsing P, Fayers P, Abildgaard N, Ahlberg L, Björkstrand B, Carlson K, Dahl IM, Forsberg K, Gulbrandsen N, Haukås E, Hjertner O, Hjorth M, Karlsson T, Knudsen LM, Nielsen JL, Linder O, Mellqvist UH, Nesthus I, Rolke J, Strandberg M, Sørbø JH, Wisløff F, Juliusson G, Turesson I; Nordic Myeloma Study Group.

Blood. 2010 Sep 2;116(9):1405-12. doi: 10.1182/blood-2009-08-237974. Epub 2010 May 6.

14.

Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndrome.

Grövdal M, Khan R, Aggerholm A, Antunovic P, Astermark J, Bernell P, Engström LM, Kjeldsen L, Linder O, Nilsson L, Olsson A, Wallvik J, Tangen JM, Oberg G, Jacobsen SE, Hokland P, Porwit A, Hellström-Lindberg E.

Clin Cancer Res. 2007 Dec 1;13(23):7107-12.

15.

Higher plasma but not intracellular concentrations after infusion with liposomal daunorubicin compared with conventional daunorubicin in adult acute myeloid leukemia.

Löfgren C, Lehmann S, Jönsson-Videsäter K, Möllgård L, Linder O, Tidefelt U, Hassan M, Paul C.

Ther Drug Monit. 2007 Oct;29(5):626-31.

PMID:
17898654
16.

Successful mobilization of Ph-negative blood stem cells with intensive chemotherapy + G-CSF in patients with chronic myelogenous leukemia in first chronic phase.

Olsson-Strömberg U, Höglund M, Björkholm M, Braide I, Carlson K, Gahrton G, Grimfors G, Hast R, Lerner R, Linder O, Ljungman P, Löfvenberg E, Malm C, Nilsson PG, Paul C, Rödjer S, Stenke L, Tidefeldt U, Turesson I, Uden AM, Wahlin A, Vilen L, Winqvist I, Zettervall O, Oberg G, Simonsson B.

Leuk Lymphoma. 2006 Sep;47(9):1768-73.

PMID:
17064986
17.

Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation.

Lenhoff S, Hjorth M, Turesson I, Westin J, Gimsing P, Wislöff F, Ahlberg L, Carlson K, Christiansen I, Dahl IM, Forsberg K, Brinch L, Hammerström J, Johnsen HE, Knudsen LM, Linder O, Mellqvist UH, Nesthus I, Nielsen JL; Nordic Myeloma Study Group.

Haematologica. 2006 Sep;91(9):1228-33.

18.

Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group.

Lenhoff S, Hjorth M, Westin J, Brinch L, Bäckström B, Carlson K, Christiansen I, Dahl IM, Gimsing P, Hammerström J, Johnsen HE, Juliusson G, Linder O, Mellqvist UH, Nesthus I, Nielsen JL, Tangen JM, Turesson I; Nordic Myeloma Study Group.

Br J Haematol. 2006 May;133(4):389-96.

PMID:
16643445
19.

A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life.

Samuelsson J, Hasselbalch H, Bruserud O, Temerinac S, Brandberg Y, Merup M, Linder O, Bjorkholm M, Pahl HL, Birgegard G; Nordic Study Group for Myeloproliferative Disorders.

Cancer. 2006 Jun 1;106(11):2397-405.

20.

Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months.

Schulman S, Lindmarker P, Holmström M, Lärfars G, Carlsson A, Nicol P, Svensson E, Ljungberg B, Viering S, Nordlander S, Leijd B, Jahed K, Hjorth M, Linder O, Beckman M.

J Thromb Haemost. 2006 Apr;4(4):734-42.

21.

Intensive treatment and stem cell transplantation in chronic myelogenous leukemia: long-term follow-up.

Simonsson B, Oberg G, Bjoreman M, Bjorkholm M, Carneskog J, Karlsson K, Gahrton G, Grimfors G, Hast R, Karle H, Linder O, Ljungman P, Nielsen JL, Nilsson J, Lofvenberg E, Malm C, Olsson K, Olsson-Stromberg U, Paul C, Stenke L, Stentoft J, Turesson I, Udén AM, Wahlin A, Vilén L, Weis-Bjerrum O.

Acta Haematol. 2005;113(3):155-62.

PMID:
15870485
22.

Autologous and allogeneic stem cell transplantation in adult ALL: the Swedish Adult ALL Group experience.

Hallböök H, Hägglund H, Stockelberg D, Nilsson PG, Karlsson K, Björkholm M, Linderholm M, Wahlin A, Linder O, Smedmyr B; Swedish Adult ALL Group.

Bone Marrow Transplant. 2005 Jun;35(12):1141-8.

PMID:
15834433
23.

Comparison of busulphan, hydroxyurea and allogeneic bone marrow transplantation (BMT) in chronic myeloid leukaemia: BMT prolongs survival.

Olsson-Strömberg U, Simonsson B, Ahlgren T, Björkholm M, Carlsson K, Gahrton G, Hast R, Löfvenberg E, Linder O, Ljungman P, Malm C, Paul C, Rödjer S, Turesson I, Udén AM, Wahlin A, Killander A, Wadman B, Westin J, Vikrot O, Zettervall O, Oberg G; Swedish CML Study Group.

Hematol J. 2004;5(6):462-6.

PMID:
15570285
24.

Acquired hemophilia masked by warfarin therapy: report on two cases.

Uggla B, Linder O, Schulman S.

Blood Coagul Fibrinolysis. 2003 Dec;14(8):769-72.

PMID:
14614359
25.

No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease.

Hast R, Hellström-Lindberg E, Ohm L, Björkholm M, Celsing F, Dahl IM, Dybedal I, Gahrton G, Lindberg G, Lerner R, Linder O, Löfvenberg E, Nilsson-Ehle H, Paul C, Samuelsson J, Tangen JM, Tidefelt U, Turesson I, Wahlin A, Wallvik J, Winquist I, Oberg G, Bernell P.

Leukemia. 2003 Sep;17(9):1827-33.

PMID:
12970783
26.

Phase II study of cyclophosphamide, interferon-alpha and betamethasone (CIB) as induction therapy for patients 60-75 years of age with multiple myeloma stages II and III.

Lundin J, Osterborg A, Björkholm M, Björkstrand B, Celsing F, Hjalmar V, Linder O, Luthman M, Merup M, Tidefelt U, Mellstedt H; Myeloma Group of Central Sweden.

Hematol J. 2003;4(4):248-52.

PMID:
12872149
27.

A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life.

Hellström-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal I, Grimfors G, Hesse-Sundin E, Hjorth M, Kanter-Lewensohn L, Linder O, Luthman M, Löfvenberg E, Oberg G, Porwit-MacDonald A, Rådlund A, Samuelsson J, Tangen JM, Winquist I, Wisloff F; Scandinavian MDS Group.

Br J Haematol. 2003 Mar;120(6):1037-46.

PMID:
12648074
28.

Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase--a report from the Swedish CML Group.

Axdorph U, Stenke L, Grimfors G, Carneskog J, Hansen J, Linder O, Ljungman P, Löfvenberg E, Malm C, Simonsson B, Turesson I, Vilén L, Udén AM, Björkholm M; Swedish CML Group.

Br J Haematol. 2002 Sep;118(4):1048-54.

PMID:
12199784
29.

High-dose cytarabine in upfront therapy for adult patients with acute lymphoblastic leukaemia.

Hallböök H, Simonsson B, Ahlgren T, Björkholm M, Carneskog J, Grimfors G, Hast R, Karlsson K, Kimby E, Lerner R, Linder O, Linderholm M, Löfvenberg E, Malm C, Nilsson PG, Paul C, Stenke L, Stockelberg D, Tidefelt U, Turesson I, Uden-Blome AM, Vilen L, Wahlin A, Winquist I, Smedmyr B.

Br J Haematol. 2002 Sep;118(3):748-54.

PMID:
12181041
30.

[LGL syndrome can imitate Felty's syndrome. The diagnosis can be established by a simple test].

Linder O, Tidefelt U.

Lakartidningen. 1999 May 26;96(21):2595-6, 2599-601. Swedish.

PMID:
10388281
31.

Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients.

Hellström-Lindberg E, Ahlgren T, Beguin Y, Carlsson M, Carneskog J, Dahl IM, Dybedal I, Grimfors G, Kanter-Lewensohn L, Linder O, Luthman M, Löfvenberg E, Nilsson-Ehle H, Samuelsson J, Tangen JM, Winqvist I, Oberg G, Osterborg A, Ost A.

Blood. 1998 Jul 1;92(1):68-75.

32.

[A party that wants to save health care].

Liljenberg J, Allgén LG, Orsten PA, Menzinsk B, Linder O, de Hevesy G.

Lakartidningen. 1997 Apr 2;94(14):1264. Swedish. No abstract available.

PMID:
9162803
33.

The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.

Schulman S, Granqvist S, Holmström M, Carlsson A, Lindmarker P, Nicol P, Eklund SG, Nordlander S, Lärfars G, Leijd B, Linder O, Loogna E.

N Engl J Med. 1997 Feb 6;336(6):393-8.

34.

[Should the guidelines on deep venous thrombosis be given the finishing touches?].

Linder O.

Lakartidningen. 1995 Mar 8;92(10):956. Swedish. No abstract available.

PMID:
7885090
35.

[Vision test of professional drivers at the Post Office].

Linder O, Wiklund PO.

Lakartidningen. 1976 May 19;73(21):2037-8. Swedish. No abstract available.

PMID:
1271945
36.

[Are individuals in training healthier than other personnel?].

Linder O, Sundsgärd B.

Lakartidningen. 1975 Apr 9;72(15):1555-6. Swedish. No abstract available.

PMID:
1134152
37.

Letter: Sex ratio in phenylketonuria.

Linder O.

N Engl J Med. 1974 Jan 3;290(1):59. No abstract available.

PMID:
4808507
38.

[Food additives--for or against?].

Linder O.

Lakartidningen. 1972 Nov 8;69(46):5274-5. Swedish. No abstract available.

PMID:
4650735
39.

[Fluoridation of drinking water is a scientific anachronism].

Linder O.

Lakartidningen. 1966 Mar 23;63(12):1167-70. Swedish. No abstract available.

PMID:
5919979
40.

Autologous skin grafting in psoriasis. Observations in the first postoperative weeks.

Linder O, Skog E.

Acta Derm Venereol. 1965;45(3):178-85. No abstract available.

PMID:
4163233
41.

Etiological problems in connection with a case of Kaposi's varicelliform eruption.

Gentele H, Linder O.

Acta Derm Venereol. 1965;45(4):319-20. No abstract available.

PMID:
4162968
42.

Immunologic studies in pathologic conditions of the skin, with special reference to psoriasis.

Skog E, Linder O.

Acta Derm Venereol. 1965;45(6):461-6. No abstract available.

PMID:
4162869
43.
44.

Modification of the homograft response after pretreatment with ovarian grafts.

LINDER OE.

Ann N Y Acad Sci. 1962 Oct 24;99:680-8. No abstract available.

PMID:
13930814
45.

Availability time of 3H-label after administration of 3H-thymidine in vivo.

DIDERHOLM H, FICHTELIUS KE, LINDER O.

Exp Cell Res. 1962 Sep;27:431-5. No abstract available.

PMID:
14027741
46.
48.

Absence of hybrid-specific histocompatibility antigens in the mouse.

WIGZELL H, LINDER OE.

Plast Reconstr Surg. 1961 Oct;28:110-3. No abstract available.

PMID:
14006902
49.
50.

Supplemental Content

Loading ...
Support Center